

Ke-Tao Jin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9108955/publications.pdf>

Version: 2024-02-01

52
papers

1,336
citations

361413

20
h-index

377865

34
g-index

52
all docs

52
docs citations

52
times ranked

2343
citing authors

#	ARTICLE	IF	CITATIONS
1	Organoid Models for Precision Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 770465.	4.8	23
2	The emerging therapeutic role of mesenchymal stem cells in anthracycline-induced cardiotoxicity. <i>Cell and Tissue Research</i> , 2021, 384, 1-12.	2.9	3
3	Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements. <i>Cancers</i> , 2021, 13, 588.	3.7	18
4	Crosstalk between oncolytic viruses and autophagy in cancer therapy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 134, 110932.	5.6	23
5	Tumor-Associated Macrophages Promote Oxaliplatin Resistance via METTL3-Mediated m ⁶ A of TRAF5 and Necroptosis in Colorectal Cancer. <i>Molecular Pharmaceutics</i> , 2021, 18, 1026-1037.	4.6	56
6	Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. <i>Cancer Cell International</i> , 2021, 21, 83.	4.1	17
7	Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets. <i>Nature Communications</i> , 2021, 12, 3946.	12.8	21
8	Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: A comprehensive review. <i>Cancer Science</i> , 2021, 112, 2592-2606.	3.9	25
9	Role of immune regulatory cells in breast cancer: Foe or friend?. <i>International Immunopharmacology</i> , 2021, 96, 107627.	3.8	12
10	A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-19.	4.0	21
11	Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold. <i>Experimental Cell Research</i> , 2021, 408, 112858.	2.6	7
12	Adenosinergic Pathway: A Hope in the Immunotherapy of Glioblastoma. <i>Cancers</i> , 2021, 13, 229.	3.7	13
13	Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?. <i>Frontiers in Oncology</i> , 2021, 11, 769305.	2.8	13
14	Long non-coding RNA DANCR promotes colorectal tumor growth by binding to lysine acetyltransferase 6A. <i>Cellular Signalling</i> , 2020, 67, 109502.	3.6	16
15	An update on colorectal cancer microenvironment, epigenetic and immunotherapy. <i>International Immunopharmacology</i> , 2020, 89, 107041.	3.8	45
16	Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective. <i>Drug Delivery</i> , 2020, 27, 1248-1262.	5.7	16
17	Recent Trends in Nanocarrier-Based Targeted Chemotherapy: Selective Delivery of Anticancer Drugs for Effective Lung, Colon, Cervical, and Breast Cancer Treatment. <i>Journal of Nanomaterials</i> , 2020, 1-14.	2.7	40
18	Nanomedicine and Early Cancer Diagnosis: Molecular Imaging using Fluorescence Nanoparticles. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 2737-2761.	2.1	12

#	ARTICLE	IF	CITATIONS
19	A potential novel therapy for FGFR1â€‘amplified pancreatic cancer with bone metastasis, screened by nextâ€‘generation sequencing and a patientâ€‘derived xenograft model. <i>Oncology Letters</i> , 2019, 17, 2303-2307.	1.8	10
20	Current progress in the clinical use of circulating tumor cells as prognostic biomarkers. <i>Cancer Cytopathology</i> , 2019, 127, 739-749.	2.4	23
21	Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase. <i>Oncology Letters</i> , 2019, 17, 3842-3850.	1.8	51
22	Garcinol inhibits cancer stem cell-like phenotype via suppression of the Wnt/ β -catenin/STAT3 axis signalling pathway in human non-small cell lung carcinomas. <i>Journal of Nutritional Biochemistry</i> , 2018, 54, 140-150.	4.2	38
23	UBASH3B promotes tamoxifen resistance and could be negatively regulated by ESR1. <i>Oncotarget</i> , 2018, 9, 8326-8333.	1.8	4
24	Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis. <i>Molecular Medicine Reports</i> , 2017, 16, 4784-4790.	2.4	9
25	Molecular Imaging of Cancer with Nanoparticle-Based Theranostic Probes. <i>Contrast Media and Molecular Imaging</i> , 2017, 2017, 1-11.	0.8	45
26	Microbiota-gut-brain axis and the central nervous system. <i>Oncotarget</i> , 2017, 8, 53829-53838.	1.8	195
27	Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 16704-16711.	1.8	37
28	Genetic heterogeneity in hepatocellular carcinoma and paired bone metastasis revealed by next-generation sequencing. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 10495-10504.	0.5	1
29	Totally laparoscopic D2 radical distal gastrectomy using Billroth II anastomosis: A case report. <i>Oncology Letters</i> , 2016, 11, 1855-1858.	1.8	2
30	Impact of Abdominal Shape on Short-Term Surgical Outcome of Laparoscopy-Assisted Distal Gastrectomy for Gastric Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1091-1097.	1.7	7
31	Establishment and characterization of GCSR1, a multi-drug resistant signet ring cell gastric cancer cell line. <i>International Journal of Oncology</i> , 2015, 46, 2479-2487.	3.3	8
32	FRZB up-regulation is correlated with hepatic metastasis and poor prognosis in colon carcinoma patients with hepatic metastasis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 4083-90.	0.5	6
33	Perineural invasion: a potential reason of hepatocellular carcinoma bone metastasis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 5839-46.	1.3	4
34	Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 8369-76.	1.3	25
35	FRZB up-regulated in hepatocellular carcinoma bone metastasis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 13353-9.	0.5	4
36	Clinical modalities for management of gastric cancer hepatic metastasis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 19850-8.	1.3	2

#	ARTICLE	IF	CITATIONS
37	Antitumor effect of FP3 in a breast cancer xenograft model. <i>Experimental and Therapeutic Medicine</i> , 2013, 5, 85-88.	1.8	1
38	Antitumor effects of FP3 in combination with capecitabine on PDDT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. <i>Cancer Biology and Therapy</i> , 2012, 13, 737-744.	3.4	5
39	Antitumor effect of FP3 in a patient-derived tumor tissue xenograft model of gastric carcinoma through an antiangiogenic mechanism. <i>Oncology Letters</i> , 2012, 3, 1052-1058.	1.8	10
40	Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. <i>International Journal of Molecular Medicine</i> , 2012, 30, 126-32.	4.0	6
41	Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases. <i>International Journal of Oncology</i> , 2012, 41, 583-588.	3.3	22
42	Mechanisms regulating colorectal cancer cell metastasis into liver (Review). <i>Oncology Letters</i> , 2012, 3, 11-15.	1.8	45
43	Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases. <i>PLoS ONE</i> , 2011, 6, e28384.	2.5	27
44	Gallbladder carcinoma incidentally encountered during laparoscopic cholecystectomy: how to deal with it. <i>Clinical and Translational Oncology</i> , 2011, 13, 25-33.	2.4	35
45	FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo. <i>Clinical and Translational Oncology</i> , 2011, 13, 878-884.	2.4	11
46	Heterogeneity in primary tumors and corresponding metastases: could it provide us with any hints to personalize cancer therapy?. <i>Personalized Medicine</i> , 2011, 8, 175-182.	1.5	9
47	Establishment of a PDDT Xenograft Model of Gastric Carcinoma and its Application in Personalized Therapeutic Regimen Selection. <i>Hepato-Gastroenterology</i> , 2011, 58, 1814-22.	0.5	21
48	Personalized cancer therapy using a patient-derived tumor tissue xenograft model: a translational field worthy of exploring further?. <i>Personalized Medicine</i> , 2010, 7, 597-606.	1.5	7
49	Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. <i>Clinical and Translational Oncology</i> , 2010, 12, 473-480.	2.4	185
50	Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?. <i>Clinical and Translational Oncology</i> , 2010, 12, 526-532.	2.4	24
51	Advances in Combination of Antiangiogenic Agents Targeting VEGF-binding and Conventional Chemotherapy and Radiation for Cancer Treatment. <i>Journal of the Chinese Medical Association</i> , 2010, 73, 281-288.	1.4	27
52	Clinical Applications of VEGF-Trap (Aflibercept) in Cancer Treatment. <i>Journal of the Chinese Medical Association</i> , 2010, 73, 449-456.	1.4	49